Assuntos
Mutação da Fase de Leitura/genética , Gota/genética , Hiperuricemia/genética , Transportadores de Ânions Orgânicos/genética , Proteínas de Transporte de Cátions Orgânicos/genética , Ácido Úrico/sangue , Adulto , Artrite Gotosa/sangue , Artrite Gotosa/genética , Gota/sangue , Homozigoto , Humanos , Hiperuricemia/sangue , Masculino , Mutagênese Insercional/genéticaRESUMO
Objetivo: Determinar la influencia de factores sociodemográficos en las manifestaciones clínicas, actividad de la enfermedad, estado funcional y calidad de vida de pacientes con artritis psoriásica (APs). Métodos: Se incluyeron 148 pacientes con APs reclutados de varios centros de reumatología de Argentina. Se determinaron factores sociodemográficos: edad, sexo, raza, nivel de educación, fuentes de ingreso personal, escala de Graffar y clases sociales. Al inicio de la enfermedad se evaluaron las siguientes variables: edad al inicio, duración de la enfermedad, manifestaciones clínicas y forma clínica de presentación. La actividad de la enfermedad fue evaluada mediante número de articulaciones activas, escala visual análoga (EVA) global del paciente y BASDAI. El estado funcional y la calidad de vida de los pacientes se determinó por medio de BASFI, ASQoL y SF-12 (Versión 1.0). Para el análisis estadístico de los datos obtenidos se utilizó test de Chi-cuadrado, test exacto de Fisher y test de Kruskal-Wallis. Resultados: De los 148 pacientes, 58,8% fueron mujeres con una edad media al inicio de la enfermedad de 53,2 ± 13,6 años y una duración media de enfermedad de 9,3 ± 8,9 años. La edad al inicio, el sexo, la raza y la escala de Graffar no estuvieron asociados con manifestaciones clínicas, actividad de la enfermedad, estado funcional y calidad de vida
Assuntos
Artrite Psoriásica , Artrite Psoriásica/economia , Artrite Psoriásica/epidemiologia , Artrite Psoriásica/etnologia , Psoríase , Qualidade de VidaRESUMO
OBJECTIVE: To describe a group of patients with frequent tophaceous gout, the variables associated with severe tophaceous gout and to compare them with other patients with gout described elsewhere. METHODS: We looked for 65 demographic clinical and paraclinical variables from patients with gout who attended our gout clinic from 1995-2000 and were evaluated by the same group of physicians. RESULTS: Three hundred and sixteen patients were included, 98% males, 82% live in México city, the mean age at onset, educational level and disease duration were 37.5 +/- 12.4, 6.3 +/- 3.9 and 12.6 +/- 10.3 years respectively. Tophaceous gout was present in 62% of the patients with a mean tophi number of 4.7 +/- 6.3 and mean HAQ score 0.13 +/- 0.37. Severe tophaceous gout (>or= 5 tophi) was found in 34% and these patients had significantly: earlier age at onset, longer duration of the disease, lesser frequency of obesity and higher frequency of: intradermal tophi, HAQ > 0.5, hospitalizations, radiographic score III/IV, uric acid under-excretion, renal function impairment and previous (oral and parenteral) auto-prescribed chronic glucocorticoid treatment compared with patients with non-severe tophaceous gout. In the multiple logistic regression the significant variables were renal function impairment (p = 0.000) and previous chronic parenteral glucocorticoid treatment (p = 0.011) . CONCLUSION: Our patients compared with those from other countries who have earlier age at onset, very low frequency of gout among females, frequent tophaceous gout and severe tophaceous gout. Severe tophaceous gout in this group is associated with renal function impairment and previous chronic parenteral glucocorticoid treatment.
Assuntos
Gota/epidemiologia , Nível de Saúde , Nefropatias/epidemiologia , Classe Social , Adulto , Idade de Início , Comorbidade , Comparação Transcultural , Feminino , Glucocorticoides/uso terapêutico , Gota/patologia , Gota/fisiopatologia , Humanos , Nefropatias/patologia , Nefropatias/fisiopatologia , Masculino , México/epidemiologia , Fatores de Risco , Índice de Gravidade de Doença , Fatores Socioeconômicos , Inquéritos e QuestionáriosRESUMO
La dermatomiositis asociada a neoplasias ha sido reportada en el 11.8 por ciento de los casos. Hasta el momento, solo se ha descrito en la literatura un caso de asociación entre dermatomiositis y adenocarcinoma de vesícula biliar. Presentamos el caso de una paciente de 53 años con debilidad muscular proximal de cinturas escapular y pélvica, manifestaciones cutáneas (Gottron y eritema en heliotropo), e incremento de enzimas musculares, en quién se hizo el diagnóstico de Dermatomiositis y se le prescribió el tratamiento adecuado sin embargo, a los 3 meses de evolución acudió con pérdida de peso, mala respuesta a esteroides y metotrexate, síndrome ictérico, hemorragia de tubo digestivo; se le realizó ultrasonido de hígado y vías biliares reportándose datos compatibles con coledocolitiasis y daño hepático difuso, se le realizó colecistectomía y el reporte histopatológico fue de adenocarcinoma de vesícula biliar. El objetivo de este reporte es la presentación del segundo caso en que asocia la dermatomiositis y el adenocarcinoma de vesícula biliar en la literatura médica internacional.
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Adenocarcinoma , Dermatomiosite , Neoplasias da Vesícula Biliar , Doenças do Tecido Conjuntivo , MiositeRESUMO
OBJECTIVE: To compare the efficacy of 2 low-dose oral methotrexate (MTX) schedules in maintaining remission in patients with rheumatoid arthritis (RA). METHODS: Patients with RA were included if they were receiving treatment with weekly MTX for at least 9 months and the RA was in remission (defined by American College of Rheumatology [ACR] criteria) for at least 6 months. Patients were stratified by treatment and randomly assigned to weekly or every-other-weekly (EOW; reducing their monthly dose by half) treatment with MTX. Patients were evaluated by a rheumatologist (blinded to the treatment schedule) at baseline and at 6, 12, and 24 weeks. The evaluations included joint counts, Ritchie Articular Index, Health Assessment Questionnaire Disability Index, physician's and patient's global health assessments, visual analog scale for pain, and incidence of adverse effects. Laboratory evaluations were done at baseline and at week 24. RESULTS: Fifty-one patients were included (26 taking weekly MTX, 25 taking EOW MTX). Baseline comparisons showed no differences between the groups. The mean duration of RA was <3 years in both groups, and they had been started on weekly MTX treatment early after diagnosis. After 24 weeks, >90% of the patients in both groups continued in remission. Evaluations of disease activity at 6 and 12 weeks showed no between-group differences. EOW MTX patients who experienced relapse were switched back to weekly MTX, and after a few weeks, their RA was again controlled. The incidence of adverse effects was slightly higher in the weekly MTX group, although the difference did not reach statistical significance. The observed laboratory values were very similar for both groups, except for the serum aspartate aminotransferase and alanine aminotransferase levels, which decreased in the EOW MTX group and were statistically significant at week 24 (P = 0.04 and P = 0.006, respectively). CONCLUSION: EOW MTX represents a valid therapeutic alternative for a specific subgroup of RA patients, as outlined by the ACR remission criteria. Patients with a short disease duration who were treated early after disease onset with weekly MTX and who achieve sustained remission have a higher probability of success with the EOW MTX schedule.